Cargando…

Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification

BACKGROUND: The aim of the study was to evaluate the efficacy of abdominopelvic lymphatic drainage area irradiation (APLN), instead of whole abdominal radiotherapy (WART), in the consolidative radiotherapy of advanced ovarian carcinoma patients. METHODS: We conducted a retrospective analysis collect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jing, Tao, Yin Jie, Guan, Hui, Zhen, Hong Nan, Dong, Ting Ting, Liu, Zhi Kai, Zhang, Fu Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239501/
https://www.ncbi.nlm.nih.gov/pubmed/35837318
http://dx.doi.org/10.14740/wjon1454
_version_ 1784737311173378048
author Shen, Jing
Tao, Yin Jie
Guan, Hui
Zhen, Hong Nan
Dong, Ting Ting
Liu, Zhi Kai
Zhang, Fu Quan
author_facet Shen, Jing
Tao, Yin Jie
Guan, Hui
Zhen, Hong Nan
Dong, Ting Ting
Liu, Zhi Kai
Zhang, Fu Quan
author_sort Shen, Jing
collection PubMed
description BACKGROUND: The aim of the study was to evaluate the efficacy of abdominopelvic lymphatic drainage area irradiation (APLN), instead of whole abdominal radiotherapy (WART), in the consolidative radiotherapy of advanced ovarian carcinoma patients. METHODS: We conducted a retrospective analysis collecting 99 patients with locally advanced ovarian cancer treated by APLN with 45 - 50 Gy/25- 28 fractions/5-7#, instead of WART. We evaluated the clinical outcome of APLN. Five patients were selected for dosimetric verifications verses WART (30 Gy/20 fractions). The normal tissue complication probability (NTCP) was calculated for the two treatment methods. RESULTS: The mean follow-up time was 64.10 months (5.5 - 113.2 months), after APLN consolidative radiotherapy, 1-, 3-, and 5-year overall survival (OS) was 87.9%, 81.3%, and 61.5%, median disease-free survival (DFS) was 40.8 months, 5-year local recurrence free survival (LRFS) was 75.9%, and 5-year distant metastasis free survival (DMFS) was 49.2%. One patient died due to intestinal perforation. Local recurrence in the area between WART and APLN was rare (3/99 patients). The number of surgical procedures < 2 was an independent risk factor for LRFS (P = 0.023). Dosimetric comparison showed that comparing with WART, APLN significantly reduced the organ at risk (OAR) dose: 25.37 ± 3.63 Gy (25%) for liver, 8.77 ± 5.03 Gy (25%) for kidney, 8.14 ± 1.51 Gy (25%) for small intestine, etc. NTCP was reduced by 0.04-1.04% for liver, kidney, and small intestine. CONCLUSION: For consolidative radiotherapy in locally advanced ovarian cancer, APLN (intensity-modulated radiotherapy 45 - 50 Gy/25 - 28 fractions) could be an alternative to WART, resulting in excellent LRFS and DFS, with acceptable toxicities, comparing with previous literature reports. Dosimetric analysis also showed the benefits of APLN in NTCP.
format Online
Article
Text
id pubmed-9239501
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-92395012022-07-13 Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification Shen, Jing Tao, Yin Jie Guan, Hui Zhen, Hong Nan Dong, Ting Ting Liu, Zhi Kai Zhang, Fu Quan World J Oncol Original Article BACKGROUND: The aim of the study was to evaluate the efficacy of abdominopelvic lymphatic drainage area irradiation (APLN), instead of whole abdominal radiotherapy (WART), in the consolidative radiotherapy of advanced ovarian carcinoma patients. METHODS: We conducted a retrospective analysis collecting 99 patients with locally advanced ovarian cancer treated by APLN with 45 - 50 Gy/25- 28 fractions/5-7#, instead of WART. We evaluated the clinical outcome of APLN. Five patients were selected for dosimetric verifications verses WART (30 Gy/20 fractions). The normal tissue complication probability (NTCP) was calculated for the two treatment methods. RESULTS: The mean follow-up time was 64.10 months (5.5 - 113.2 months), after APLN consolidative radiotherapy, 1-, 3-, and 5-year overall survival (OS) was 87.9%, 81.3%, and 61.5%, median disease-free survival (DFS) was 40.8 months, 5-year local recurrence free survival (LRFS) was 75.9%, and 5-year distant metastasis free survival (DMFS) was 49.2%. One patient died due to intestinal perforation. Local recurrence in the area between WART and APLN was rare (3/99 patients). The number of surgical procedures < 2 was an independent risk factor for LRFS (P = 0.023). Dosimetric comparison showed that comparing with WART, APLN significantly reduced the organ at risk (OAR) dose: 25.37 ± 3.63 Gy (25%) for liver, 8.77 ± 5.03 Gy (25%) for kidney, 8.14 ± 1.51 Gy (25%) for small intestine, etc. NTCP was reduced by 0.04-1.04% for liver, kidney, and small intestine. CONCLUSION: For consolidative radiotherapy in locally advanced ovarian cancer, APLN (intensity-modulated radiotherapy 45 - 50 Gy/25 - 28 fractions) could be an alternative to WART, resulting in excellent LRFS and DFS, with acceptable toxicities, comparing with previous literature reports. Dosimetric analysis also showed the benefits of APLN in NTCP. Elmer Press 2022-06 2022-06-22 /pmc/articles/PMC9239501/ /pubmed/35837318 http://dx.doi.org/10.14740/wjon1454 Text en Copyright 2022, Shen et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shen, Jing
Tao, Yin Jie
Guan, Hui
Zhen, Hong Nan
Dong, Ting Ting
Liu, Zhi Kai
Zhang, Fu Quan
Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
title Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
title_full Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
title_fullStr Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
title_full_unstemmed Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
title_short Abdominopelvic Lymphatic Drainage Area Irradiation for Consolidative Radiotherapy of Advanced Ovarian Carcinoma: Analysis of Clinical Application Efficacy and Dosimetric Verification
title_sort abdominopelvic lymphatic drainage area irradiation for consolidative radiotherapy of advanced ovarian carcinoma: analysis of clinical application efficacy and dosimetric verification
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239501/
https://www.ncbi.nlm.nih.gov/pubmed/35837318
http://dx.doi.org/10.14740/wjon1454
work_keys_str_mv AT shenjing abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification
AT taoyinjie abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification
AT guanhui abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification
AT zhenhongnan abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification
AT dongtingting abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification
AT liuzhikai abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification
AT zhangfuquan abdominopelviclymphaticdrainageareairradiationforconsolidativeradiotherapyofadvancedovariancarcinomaanalysisofclinicalapplicationefficacyanddosimetricverification